Human serum enhances the proliferative capacity and immunomodulatory property of MSCs derived from human placenta and umbilical cord

• Published in: Stem cell research & therapy Vol. 10; no. 1; p. 79
• Main Authors: Thaweesapphithak, Sermporn, Tantrawatpan, Chairat, Kheolamai, Pakpoom, Tantikanlayaporn, Duangrat, Roytrakul, Sittiruk, Manochantr, Sirikul
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.03.2019; BioMed Central; BMC
• Subjects: Bone marrow; Cell growth; Cell Proliferation; Clinical trials; Con-A; Female; Fetal calf serum; Gene expression; Glycoproteins; Good Manufacturing Practice; Human serum; Humans; Immunomodulation; Immunosuppression; Immunotherapy; Manufacturing; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - immunology; Mesenchymal stromal cell; Mesenchyme; Molecular weight; Physical characteristics; Placenta; Placenta - cytology; Placenta - immunology; Pregnancy; Production management; Serum; Stem cells; Stromal cells; Studies; Therapeutic applications; Transplants & implants; Umbilical cord; Umbilical Cord - cytology; Umbilical Cord - immunology; WGA; Human serum; Con-A; Immunosuppression; Placenta; Mesenchymal stromal cell; Umbilical cord
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-019-1175-3

Mesenchymal stromal cells (MSCs) are considered potential candidates that hold great promise in the treatment of immune-related diseases. For therapeutic applications, it is necessary to isolate and expand MSCs with procedures complying with good manufacturing practice (GMP). Recent studies reported the use of human serum (HS) instead of fetal bovine serum (FBS) for the expansion of bone marrow-derived MSCs. Nevertheless, there are only limited data on HS as an alternative to FBS for the isolation and expansion of umbilical (UC-MSCs) and placenta-derived MSCs (PL-MSCs). In this study, we evaluate the effect of HS compared to FBS on the proliferative and immunosuppressive capacities of these MSCs. PL-MSCs and UC-MSCs were isolated and cultured in HS- or FBS-supplemented media. The MSC characteristics, including morphology, immunophenotype, and differentiation ability, were verified. The proliferative and immunosuppressive capacities were also examined. In addition, the proliferative-enhancing factors in both sera were explored using proteomic analysis. PL-MSCs and UC-MSCs proliferated faster in HS-supplemented medium than in equivalent levels of FBS-supplemented medium. Adipogenic and osteogenic differentiations occurred at nearly identical levels in HS- and FBS-supplemented media. Interestingly, MSCs cultured in HS-supplemented medium had a similar immunosuppressive effect as MSCs cultured in FBS-supplemented medium. Proteomic analysis revealed that Con-A binding glycoproteins with a molecular weight > 100 kDa in FBS could significantly enhance MSC proliferation. In contrast, the proliferative enhancing factors in HS were found in the Con-A non-binding fraction and WGA binding fraction with a molecular weight > 100 kDa. Taken together, our results suggest applications for the use of HS instead of FBS for the isolation and expansion of PL-MSCs and UC-MSCs for cell therapy in the future. Furthermore, this study identifies factors in HS that are responsible for its proliferative and immunosuppressive effects and might thus lead to the establishment of GMPs for the therapeutic use of MSCs.